PMID- 35045672
OWN - NLM
STAT- MEDLINE
DCOM- 20220121
LR  - 20220214
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 42
IP  - 12
DP  - 2021 Dec 14
TI  - [Immunoglobulin M multiple myeloma: a six-case report and literature review].
PG  - 1011-1014
LID - 10.3760/cma.j.issn.0253-2727.2021.12.008 [doi]
AB  - Objective: To investigate the clinical characteristics, responses, and prognosis 
      of immunoglobulin M multiple myeloma (IgM MM) . Methods: The clinical 
      characteristics, laboratory results, bone marrow biopsy results, response, and 
      prognosis of six cases of IgM MM in the Blood Diseases Hospital, Chinese Academy 
      of Medical Sciences, from December 18, 2009 to October 29, 2020 were collected 
      and analyzed. Results: All six cases met the diagnosis criteria of IgM MM. There 
      were four males and two females. The median age at first diagnosis was 70 (59-81) 
      years. According to Durie-Salmon (DS) staging, 2 cases were in ⅠA, and 4 cases 
      were in ⅢA. According to the International Staging System (ISS) , 4 cases were in 
      Ⅱ, and 2 cases were in Ⅲ. The initial symptoms were as follows: 4 cases of bone 
      pain, 3 cases of hyperviscosity, and 2 cases of lymphadenopathy or 
      hepatosplenomegaly. Laboratory results showed the following: median blood M 
      protein: 39.11 (3.61-75.56) g/L; median serum IgM: 69.35 (4.35-137.00) g/L; 
      median hemoglobin: 87.0 (70-131) g/L; median blood creatinine: 83.6 (53.0-129.6) 
      mumol/L; median blood calcium: 2.12 (2.11-2.50) mmol/L. The median ratio of bone 
      marrow plasma cells was 0.390 (0.255-0.590) , and in four cases, plasma cells 
      were observed in blood smears. Karyotype analysis and fluorescence in situ 
      hybridization (FISH) examination showed the following: 1 case of hypodiploidy, 2 
      cases of P53 gene deletion, 1 case of 1q21 amplification positive, and 4 cases of 
      RB-1 gene deletion positive. The immunoglobulin heavy chain (IgH) rearrangement 
      was positive in all cases, of which 3 cases were CCND1/IgH fusion gene-positive 
      identified with t (11;14) rearrangement. Immunophenotyping revealed that all 
      cases were positive for CD38, CD138, and monoclonal light chain and four cases 
      were weakly positive for CD20. All cases accepted proteasome inhibitor-based 
      regimens and attained the response of partial remission to strict complete 
      remission. Conclusion: In addition to the typical clinical manifestations of 
      myeloma, IgM MM is also characterized by hyperviscosity, lymphadenopathy, or 
      hepatosplenomegaly, and t (11;14) is the most frequent cytogenetics aberration. 
      Furthermore, the response and prognosis of IgM MM are similar to other common 
      myeloma subtypes.
FAU - Yan, W W
AU  - Yan WW
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Fan, H S
AU  - Fan HS
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Xu, J Y
AU  - Xu JY
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Liu, J H
AU  - Liu JH
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Du, C X
AU  - Du CX
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Deng, S H
AU  - Deng SH
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Sui, W W
AU  - Sui WW
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Xu, Y
AU  - Xu Y
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - Qiu, L G
AU  - Qiu LG
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
FAU - An, G
AU  - An G
AD  - State Key Laboratory of Experimental Hematology, National Clinical Research 
      Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, 
      Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 
      300020, China.
LA  - chi
GR  - 81920108006/International Cooperation and Exchanges Project of National Natural 
      Science Foundation of China/
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Female
MH  - Humans
MH  - Immunoglobulin M
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - *Multiple Myeloma/diagnosis
MH  - Plasma Cells
MH  - Prognosis
PMC - PMC8770889
OTO - NOTNLM
OT  - Hyperviscosity
OT  - Immunoglobulin M
OT  - Multiple myeloma
EDAT- 2022/01/21 06:00
MHDA- 2022/01/22 06:00
PMCR- 2021/12/01
CRDT- 2022/01/20 01:32
PHST- 2022/01/20 01:32 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/22 06:00 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
AID - cjh-42-12-1011 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2021.12.008 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2021 Dec 14;42(12):1011-1014. doi: 
      10.3760/cma.j.issn.0253-2727.2021.12.008.